MA56226A - Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale - Google Patents

Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale

Info

Publication number: MA56226A
Authority: MA; Morocco
Prior art keywords: treatment; receptor antagonist; pharmaceutical formulations; solid forms; adrenal hyperplasia
Prior art date: 2018-12-07

Application number

MA056226A

Other languages

English (en)

Other versions

MA56226B1 (fr

Inventor

Jean L Chan

Anne Charlier

Christina Marie Costa

Kristie M Downing

Robert H Farber

Nagdeep Giri

Kingsley Iyoha

Gordon Raphael Loewen

Gurvinder Singh Mehton

Ayanda Ngwenya-Jones

Stacy Parks

Brian Sayers

Scott Stirn

Graeme Taylor

Anthony D Vickery

Xiaoping Zhang

Original Assignee

Neurocrine Biosciences Inc

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-12-07

Filing date

2019-12-06

Publication date

2022-04-20

2019-12-06 Application filed by Neurocrine Biosciences Inc, Sanofi Sa filed Critical Neurocrine Biosciences Inc

2022-04-20 Publication of MA56226A publication Critical patent/MA56226A/fr

2025-11-28 Publication of MA56226B1 publication Critical patent/MA56226B1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/44—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers
- C07C209/52—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers by reduction of imines or imino-ethers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C249/02—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of compounds containing imino groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
- C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dispersion Chemistry (AREA)
Biochemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Inorganic Chemistry (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

MA56226A 2018-12-07 2019-12-06 Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale MA56226B1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201862776763P	2018-12-07	2018-12-07
US201962816674P	2019-03-11	2019-03-11
EP21213854.9A EP3984523B1 (fr)	2018-12-07	2019-12-06	Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale

Publications (2)

Publication Number	Publication Date
MA56226A true MA56226A (fr)	2022-04-20
MA56226B1 MA56226B1 (fr)	2025-11-28

Family

ID=69500780

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA56226A MA56226B1 (fr)	2018-12-07	2019-12-06	Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale
MA054395A MA54395A (fr)	2018-12-07	2019-12-06	Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
MA054395A MA54395A (fr)	2018-12-07	2019-12-06	Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale

Country Status (26)

Country	Link
US (4)	US20220023266A1 (fr)
EP (4)	EP3984523B1 (fr)
JP (6)	JP7238130B2 (fr)
KR (2)	KR20210100669A (fr)
CN (7)	CN113518616B (fr)
AU (3)	AU2019393256B2 (fr)
BR (1)	BR112021010847A2 (fr)
CA (3)	CA3121920A1 (fr)
DK (1)	DK3984523T3 (fr)
ES (1)	ES3052613T3 (fr)
FI (1)	FI3984523T3 (fr)
HR (1)	HRP20251224T1 (fr)
IL (2)	IL283712A (fr)
LT (1)	LT3984523T (fr)
MA (2)	MA56226B1 (fr)
MX (3)	MX2021006552A (fr)
PH (1)	PH12021551290A1 (fr)
PL (1)	PL3984523T3 (fr)
PT (1)	PT3984523T (fr)
RS (1)	RS67433B1 (fr)
SA (1)	SA521421973B1 (fr)
SG (1)	SG11202105930QA (fr)
SI (1)	SI3984523T1 (fr)
SM (1)	SMT202500435T1 (fr)
TW (3)	TW202446384A (fr)
WO (3)	WO2020115555A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3096756T3 (da) *	2014-01-21	2024-08-05	Neurocrine Biosciences Inc	CRF1-receptorantagonister til behandling af medfødt adrenal hyperplasi
US20210361664A1 (en)	2017-08-14	2021-11-25	Spruce Biosciences, Inc.	Corticotropin releasing factor receptor antagonists
TW202446384A (zh)	2018-12-07	2024-12-01	美商紐羅克里生物科學有限公司	用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式
CN114423436A (zh)	2019-07-19	2022-04-29	云杉生物科学公司	治疗先天性肾上腺增生症的方法
CN114502162B (zh)	2019-09-27	2025-03-28	纽罗克里生物科学有限公司	Crf受体拮抗剂及使用方法
US20230255942A1 (en) *	2020-06-10	2023-08-17	Neurocrine Biosciences, Inc.	Crf1 receptor antagonist for the treatment of congenital adrenal hyperplasia
CA3188730A1 (fr)	2020-08-12	2022-02-17	Christopher Barnes	Procedes et compositions pour traiter le syndrome des ovaires polykystiques
EP4308553A4 (fr)	2021-03-19	2025-01-22	Crinetics Pharmaceuticals, Inc.	Antagoniste du récepteur du sous-type 2 de la mélanocortine (mc2r) pour le traitement d'une maladie
WO2023049689A1 (fr) *	2021-09-21	2023-03-30	Reveragen Biopharma, Inc.	Traitement de l'hypoplasie surrénale congénitale
WO2023163945A1 (fr) *	2022-02-23	2023-08-31	Crinetics Pharmaceuticals, Inc.	Traitement de l'hyperplasie surrénale congénitale et du syndrome des ovaires polykystiques
CN114715871B (zh) *	2022-04-26	2023-09-12	四川朗晟新材料科技有限公司	一种锂电池用改性磷酸铁锂正极材料及制备方法
IL316629A (en) *	2022-05-11	2024-12-01	Lilly Co Eli	GLP1 drug compounds
WO2024233525A1 (fr)	2023-05-08	2024-11-14	Neurocrine Biosciences, Inc.	Schéma posologique de crinecerfont pour le traitement de l'hyperplasie surrénalienne congénitale chez un sujet pédiatrique

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS4949582B1 (fr)	1969-01-20	1974-12-27
US4783443A (en)	1986-03-03	1988-11-08	The University Of Chicago	Amino acyl cephalosporin derivatives
FR2692893B1 (fr)	1992-06-24	1994-09-02	Sanofi Elf	Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
US6664261B2 (en)	1996-02-07	2003-12-16	Neurocrine Biosciences, Inc.	Pyrazolopyrimidines as CRF receptor antagonists
TW477787B (en)	1996-08-27	2002-03-01	Pfizer	Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
AU4270297A (en)	1996-09-16	1998-04-02	Du Pont Pharmaceuticals Company	Pyrazinones and triazinones and their derivatives thereof
FR2754258B1 (fr)	1996-10-08	1998-12-31	Sanofi Sa	Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
ES2207834T3 (es)	1997-04-22	2004-06-01	Janssen Pharmaceutica N.V.	Quino- y quinazolinas antagonistas del crf.
WO1999010350A1 (fr)	1997-08-22	1999-03-04	Du Pont Pharmaceuticals Company	IMIDAZO[4,5c]PYRAZOLES A SUBSTITUTION AZOTE, EN TANT QU'ANTAGONISTES DE L'HORMONE DE LIBERATION DE LA CORTICOTROPINE
US6365180B1 (en)	1998-01-20	2002-04-02	Glenn A. Meyer	Oral liquid compositions
US6531475B1 (en)	1998-11-12	2003-03-11	Neurocrine Biosciences, Inc.	CRF receptor antagonists and methods relating thereto
AU3931400A (en)	1999-04-02	2000-10-23	Neurogen Corporation	N-benzimidazolylmethyl- and n-indolylmethyl-benzamides and their use as crf modulators
FR2796380B3 (fr)	1999-07-15	2001-08-17	Sanofi Synthelabo	Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
FR2802530B1 (fr)	1999-12-17	2002-02-22	Sanofi Synthelabo	Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
JP3830727B2 (ja)	2000-05-11	2006-10-11	セントラル硝子株式会社	光学活性α−メチル−ビス−３，５−（トリフルオロメチル）ベンジルアミンの製造方法
WO2003006015A1 (fr)	2001-07-13	2003-01-23	Bristol-Myers Squibb Pharma Company	Thiazoles et oxazoles substitutes utilises comme ligands hormonaux de liberation de la corticotrophine
WO2003022820A1 (fr)	2001-09-06	2003-03-20	Bristol-Myers Squibb Pharma Company.	Cyclopropane hetero-aromatique substitue utilise comme hormone adrenocorticotrope
RU2006129307A (ru)	2004-02-13	2008-02-20	Пфайзер Продактс Инк. (Us)	Терапевтические комбинации атипичных нейролептиков с антагонистами кортикотропин-рилизинг фактора
US20060078623A1 (en)	2004-08-13	2006-04-13	Emisphere Technologies, Inc.	Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
EP1802621B1 (fr)	2004-10-19	2009-05-06	SmithKline Beecham (Cork) Limited	Antagonistes du recepteur du crf et procedes associes
GB0519957D0 (en)	2005-09-30	2005-11-09	Sb Pharmco Inc	Chemical compound
JP4971300B2 (ja)	2005-03-21	2012-07-11	イーライリリーアンドカンパニー	イミダゾピリダジン化合物
WO2006107784A1 (fr)	2005-04-05	2006-10-12	Eli Lilly And Company	Composes d’imidazopyridazine
TWI370820B (en)	2005-04-27	2012-08-21	Takeda Pharmaceutical	Fused heterocyclic compounds
WO2006126718A1 (fr)	2005-05-27	2006-11-30	Tanabe Seiyaku Co., Ltd.	Dérivé de pyrazolopyrimidine
EP2361619A1 (fr)	2005-11-10	2011-08-31	TopoTarget UK Limited	Inhibiteurs d'histone deacetylase (hdac) (pxd-101) pour le traitement du cancer hématologique
WO2007069565A1 (fr)	2005-12-12	2007-06-21	Ono Pharmaceutical Co., Ltd.	Compose heterocyclique bicyclique
US20100184771A1 (en)	2005-12-15	2010-07-22	Ono Pharmaceutical Co., Ltd.	Bicyclic Heterocyclic Compound
ES2435793T3 (es) *	2006-02-07	2013-12-23	Phenoquest Ag	Procedimientos para el tratamiento de trastornos afectivos
JP2009529541A (ja)	2006-03-09	2009-08-20	ファーマコピアインコーポレーテッド	代謝性障害治療のための８−ヘテロアリ−ルプリンのｍｎｋ２阻害剤
EP1834641A1 (fr)	2006-03-16	2007-09-19	Sanofi-Aventis	Antagonistes du CRF1 pour la préparation de médicaments pour le traitement du syndrome métabolique et/ou de l'obesité et/ou de la dyslipoproteinemie
MX2008014843A (es)	2006-05-22	2008-12-05	Vanda Pharmaceuticals Inc	Tratamiento de trastornos depresivos.
SI2094709T1 (sl)	2006-09-20	2011-01-31	Lilly Co Eli	Tiazol pirazolopirimidini kot antagonisti crf1 receptorja
US8110580B2 (en)	2006-09-20	2012-02-07	Eli Lilly And Company	Thiophene pyrazolopyrimidine compounds
US20100056515A1 (en)	2006-10-25	2010-03-04	Kazuyoshi Aso	Benzimidazole compounds
US8039500B2 (en)	2006-12-29	2011-10-18	Takeda Pharmaceutical Company Limited	Fused heterocyclic compounds
WO2008083070A1 (fr)	2006-12-29	2008-07-10	Neurogen Corporation	Ligands des récepteurs du crf1 comprenant des groupes fonctionnels hétéroaryle bicycliques
TW200902019A (en)	2007-04-26	2009-01-16	Ono Pharmaceutical Co	Dicyclic heterocyclic compound
WO2009008552A1 (fr)	2007-07-11	2009-01-15	Taisho Pharmaceutical Co., Ltd.	Dérivés de 8-aryl-4-alkylpyrrolo[2,3,4-dé]quinoléine-5(4h)-one et de 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-dé]quinoléine-5-ol
CN101381314A (zh)	2007-09-05	2009-03-11	成都和康药业有限责任公司	(r)-(+)-n-炔丙基-1-茚胺的一种新的制备方法
WO2009042166A1 (fr)	2007-09-25	2009-04-02	Panacos Pharmaceuticals, Inc.	Formes de dosage de bevirimat liquide pour une administration orale
WO2009144632A1 (fr)	2008-05-30	2009-12-03	Pfizer Limited	Nouveaux composés
US7932256B2 (en)	2008-07-31	2011-04-26	Bristol-Myers Squibb Company	(S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
JP2011529899A (ja)	2008-07-31	2011-12-15	ブリストル−マイヤーズスクイブカンパニー	副腎皮質刺激ホルモン放出因子受容体活性のモジュレーターとしての置換カルバメート誘導体
US7994203B2 (en)	2008-08-06	2011-08-09	Novartis Ag	Organic compounds
US8273900B2 (en)	2008-08-07	2012-09-25	Novartis Ag	Organic compounds
CN102245117B (zh)	2008-11-03	2014-04-16	斯恩蒂斯有限公司	可调节的杆组件
US8551996B2 (en)	2009-02-20	2013-10-08	Emory University	Compounds, compositions, methods of synthesis, and methods of treatment
HUP0900267A2 (en)	2009-04-30	2011-03-28	Sanofi Aventis	Process for preparing of thiazole amines and intermediates thereof
WO2011043387A1 (fr)	2009-10-08	2011-04-14	エーザイ・アール・アンド・ディー・マネジメント株式会社	Composé de pyrazolooxazole
AR078521A1 (es)	2009-10-08	2011-11-16	Eisai R&D Man Co Ltd	Compuesto pirazolotiazol
AR080055A1 (es)	2010-02-01	2012-03-07	Novartis Ag	Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
AR080056A1 (es)	2010-02-01	2012-03-07	Novartis Ag	Derivados de ciclohexil-amida como antagonistas de los receptores de crf
WO2011095450A1 (fr)	2010-02-02	2011-08-11	Novartis Ag	Dérivés de cyclohexylamide à titre d'antagonistes du récepteur crf
DE102010015143A1 (de)	2010-04-16	2011-10-20	Cts Chemical Industries Ltd.	Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon
MY158809A (en) *	2010-09-22	2016-11-15	Craun Res Sdn Bhd	Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
RU2699546C2 (ru)	2012-04-13	2019-09-06	Эпизайм, Инк.	Комбинированная терапия для лечения рака
EP2841595A2 (fr)	2012-04-23	2015-03-04	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Prédicteurs génétiques de réponse à un traitement avec des antagonistes de crhr1
HK1207304A1 (en)	2012-04-23	2016-01-29	Hmnc Value Gmbh	Crhr1 antagonists for use in the treatment of patients having crh overactivity
EP3795141B1 (fr)	2013-01-14	2025-07-30	InFirst Healthcare Limited	Compositions de solution solide
EP2983525B1 (fr)	2013-03-15	2017-12-13	Virun, Inc.	Compositions comprenant des derives solubles de la vitamine e
US9351517B2 (en)	2013-03-15	2016-05-31	Virun, Inc.	Formulations of water-soluble derivatives of vitamin E and compositions containing same
DK3096756T3 (da) *	2014-01-21	2024-08-05	Neurocrine Biosciences Inc	CRF1-receptorantagonister til behandling af medfødt adrenal hyperplasi
TWI690521B (zh)	2014-04-07	2020-04-11	美商同步製藥公司	作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
WO2015159170A2 (fr)	2014-04-18	2015-10-22	Suven Life Sciences Limited	Procédé amélioré pour la synthèse de 1-(4-méthoxyphényl) éthylamine et ses isomères
WO2016065177A1 (fr) *	2014-10-22	2016-04-28	The Trustees Of The University Of Pennsylvania	Procede de traitement de la depression et d'autres troubles lies au stress
EP3253752B1 (fr)	2015-02-06	2023-08-16	Neurocrine Biosciences, Inc.	[9,10-diméthoxy-3-(2-méthylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinéloin-2-yl]méthanol et composés, compositions et procédés associés
WO2016156576A1 (fr) *	2015-04-02	2016-10-06	Hmnc Value Gmbh	Méthode de traitement utilisant les prédicteurs génétiques d'une réponse à un traitement basé sur des antagonistes du crhr1
WO2017031325A1 (fr)	2015-08-18	2017-02-23	Forum Pharmaceuticals Inc.	Composés d'oxadiazine et leurs procédés d'utilisation
EP3548035A4 (fr)	2016-11-30	2020-07-22	Case Western Reserve University	Combinaisons d'inhibiteurs de 15-pgdh avec des corcostéroïdes et/ou des inhibiteurs du tnf et leurs utilisations
WO2018219804A1 (fr) *	2017-06-02	2018-12-06	Bayer Pharma Aktiengesellschaft	Systèmes d'administration de médicaments auto-émulsifiants
US20210361664A1 (en)	2017-08-14	2021-11-25	Spruce Biosciences, Inc.	Corticotropin releasing factor receptor antagonists
CN110997667A (zh)	2017-08-14	2020-04-10	云杉生物科学公司	促肾上腺皮质激素释放因子受体拮抗剂
BR112020024062A2 (pt)	2018-04-27	2021-02-09	Spruce Biosciences, Inc.	métodos para o tratamento de tumores de restos adrenais de testículo e de ovário
TW202446384A (zh)	2018-12-07	2024-12-01	美商紐羅克里生物科學有限公司	用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式
CN114423436A (zh)	2019-07-19	2022-04-29	云杉生物科学公司	治疗先天性肾上腺增生症的方法
CN114502162B (zh)	2019-09-27	2025-03-28	纽罗克里生物科学有限公司	Crf受体拮抗剂及使用方法
ES3039926T3 (en)	2019-12-04	2025-10-27	Neurocrine Biosciences Inc	Crf receptor antagonists and methods of use
US20230255942A1 (en)	2020-06-10	2023-08-17	Neurocrine Biosciences, Inc.	Crf1 receptor antagonist for the treatment of congenital adrenal hyperplasia
CA3188730A1 (fr)	2020-08-12	2022-02-17	Christopher Barnes	Procedes et compositions pour traiter le syndrome des ovaires polykystiques
EP4203964A1 (fr)	2020-08-26	2023-07-05	Neurocrine Biosciences, Inc.	Antagonistes du récepteur crf et méthodes d'utilisation
GB202100526D0 (en)	2021-01-15	2021-03-03	Redx Pharma Plc	Pharmaceutical formulation
US20240100165A1 (en)	2021-03-04	2024-03-28	Evonik Operations Gmbh	Solid snedds based on a specific mixture of acrylic polymers

2019
- 2019-12-06 TW TW113105833A patent/TW202446384A/zh unknown
- 2019-12-06 MA MA56226A patent/MA56226B1/fr unknown
- 2019-12-06 LT LTEP21213854.9T patent/LT3984523T/lt unknown
- 2019-12-06 EP EP21213854.9A patent/EP3984523B1/fr active Active
- 2019-12-06 CA CA3121920A patent/CA3121920A1/fr active Pending
- 2019-12-06 CN CN201980080385.8A patent/CN113518616B/zh active Active
- 2019-12-06 DK DK21213854.9T patent/DK3984523T3/da active
- 2019-12-06 KR KR1020217020735A patent/KR20210100669A/ko not_active Ceased
- 2019-12-06 MX MX2021006552A patent/MX2021006552A/es unknown
- 2019-12-06 EP EP19848938.7A patent/EP3890706A2/fr active Pending
- 2019-12-06 JP JP2021531723A patent/JP7238130B2/ja active Active
- 2019-12-06 US US17/311,310 patent/US20220023266A1/en active Pending
- 2019-12-06 BR BR112021010847-5A patent/BR112021010847A2/pt unknown
- 2019-12-06 PT PT212138549T patent/PT3984523T/pt unknown
- 2019-12-06 SI SI201930979T patent/SI3984523T1/sl unknown
- 2019-12-06 CN CN202511351812.5A patent/CN121129756A/zh active Pending
- 2019-12-06 RS RS20251077A patent/RS67433B1/sr unknown
- 2019-12-06 FI FIEP21213854.9T patent/FI3984523T3/fi active
- 2019-12-06 WO PCT/IB2019/001325 patent/WO2020115555A2/fr not_active Ceased
- 2019-12-06 MA MA054395A patent/MA54395A/fr unknown
- 2019-12-06 SM SM20250435T patent/SMT202500435T1/it unknown
- 2019-12-06 PL PL21213854.9T patent/PL3984523T3/pl unknown
- 2019-12-06 PH PH1/2021/551290A patent/PH12021551290A1/en unknown
- 2019-12-06 HR HRP20251224TT patent/HRP20251224T1/hr unknown
- 2019-12-06 SG SG11202105930QA patent/SG11202105930QA/en unknown
- 2019-12-06 TW TW108144813A patent/TWI874339B/zh active
- 2019-12-06 CN CN202510478849.8A patent/CN120284862A/zh active Pending
- 2019-12-06 AU AU2019393256A patent/AU2019393256B2/en active Active
- 2019-12-06 ES ES21213854T patent/ES3052613T3/es active Active
2020
- 2020-06-10 EP EP20753411.6A patent/EP4069682A1/fr active Pending
- 2020-06-10 CN CN202080095702.6A patent/CN115087647A/zh active Pending
- 2020-06-10 CA CA3160738A patent/CA3160738A1/fr active Pending
- 2020-06-10 US US17/782,617 patent/US20230286932A1/en active Pending
- 2020-06-10 WO PCT/IB2020/000575 patent/WO2021111179A1/fr not_active Ceased
- 2020-06-10 JP JP2022533467A patent/JP7675717B6/ja active Active
- 2020-12-03 TW TW109142645A patent/TWI895302B/zh active
2021
- 2021-05-06 SA SA521421973A patent/SA521421973B1/ar unknown
- 2021-06-03 MX MX2024001849A patent/MX2024001849A/es unknown
- 2021-06-06 IL IL283712A patent/IL283712A/en unknown
- 2021-06-09 US US18/009,662 patent/US20230233534A1/en not_active Abandoned
- 2021-06-09 CN CN202510721632.5A patent/CN120817912A/zh active Pending
- 2021-06-09 CN CN202180055872.6A patent/CN116322668A/zh active Pending
- 2021-06-09 CN CN202510721890.3A patent/CN120829398A/zh active Pending
- 2021-06-09 KR KR1020237000554A patent/KR20230038185A/ko active Pending
- 2021-06-09 MX MX2022015551A patent/MX2022015551A/es unknown
- 2021-06-09 CA CA3181126A patent/CA3181126A1/fr active Pending
- 2021-06-09 EP EP21751605.3A patent/EP4164604A2/fr active Pending
- 2021-06-09 IL IL298927A patent/IL298927A/en unknown
- 2021-06-09 AU AU2021289538A patent/AU2021289538A1/en active Pending
- 2021-06-09 JP JP2022575997A patent/JP2023530084A/ja not_active Withdrawn
- 2021-06-09 WO PCT/IB2021/000403 patent/WO2021250468A2/fr not_active Ceased
2023
- 2023-06-09 JP JP2023095439A patent/JP2023105239A/ja active Pending
2024
- 2024-03-14 US US18/604,836 patent/US12128033B2/en active Active
- 2024-12-26 JP JP2024229761A patent/JP2025036615A/ja active Pending
2025
- 2025-07-03 AU AU2025205083A patent/AU2025205083A1/en active Pending
- 2025-07-16 JP JP2025119617A patent/JP2025157396A/ja active Pending

Also Published As

Publication number	Publication date
LT3984523T (lt)	2025-12-10
TW202033193A (zh)	2020-09-16
IL298927A (en)	2023-02-01
TWI895302B (zh)	2025-09-01
MX2021006552A (es)	2021-07-07
US12128033B2 (en)	2024-10-29
IL283712A (en)	2021-07-29
SG11202105930QA (en)	2021-07-29
SA521421973B1 (ar)	2024-05-12
US20240238257A1 (en)	2024-07-18
CN120829398A (zh)	2025-10-24
EP4069682A1 (fr)	2022-10-12
WO2021111179A1 (fr)	2021-06-10
JP2025157396A (ja)	2025-10-15
MX2022015551A (es)	2023-02-27
US20220023266A1 (en)	2022-01-27
JP2025036615A (ja)	2025-03-14
JP2023105239A (ja)	2023-07-28
MA56226B1 (fr)	2025-11-28
EP3890706A2 (fr)	2021-10-13
AU2025205083A1 (en)	2025-07-24
CN113518616B (zh)	2025-10-14
CN113518616A (zh)	2021-10-19
CA3160738A1 (fr)	2021-06-10
JP2022508317A (ja)	2022-01-19
DK3984523T3 (da)	2025-09-29
AU2019393256A1 (en)	2021-07-29
CN120284862A (zh)	2025-07-11
EP4164604A2 (fr)	2023-04-19
CN116322668A (zh)	2023-06-23
US20230233534A1 (en)	2023-07-27
WO2021111179A8 (fr)	2022-07-14
MA54395A (fr)	2022-03-16
HRP20251224T1 (hr)	2025-12-19
JP7675717B6 (ja)	2025-06-23
FI3984523T3 (fi)	2025-10-21
CN121129756A (zh)	2025-12-16
WO2021250468A8 (fr)	2022-08-04
TW202446384A (zh)	2024-12-01
KR20210100669A (ko)	2021-08-17
JP7675717B2 (ja)	2025-05-13
CN120817912A (zh)	2025-10-21
EP3984523A1 (fr)	2022-04-20
RS67433B1 (sr)	2025-12-31
PT3984523T (pt)	2025-10-28
WO2021250468A3 (fr)	2022-01-20
US20230286932A1 (en)	2023-09-14
WO2021250468A2 (fr)	2021-12-16
WO2020115555A3 (fr)	2020-08-06
MX2024001849A (es)	2024-02-29
PH12021551290A1 (en)	2022-03-28
SMT202500435T1 (it)	2026-01-12
JP2023530084A (ja)	2023-07-13
WO2020115555A2 (fr)	2020-06-11
JP7238130B2 (ja)	2023-03-13
TW202136225A (zh)	2021-10-01
ES3052613T3 (en)	2026-01-12
EP3984523B1 (fr)	2025-09-03
KR20230038185A (ko)	2023-03-17
AU2021289538A1 (en)	2023-02-09
CA3181126A1 (fr)	2021-12-16
AU2021289538A8 (en)	2023-06-15
SI3984523T1 (sl)	2026-01-30
AU2019393256B2 (en)	2025-07-31
BR112021010847A2 (pt)	2021-09-08
CN115087647A (zh)	2022-09-20
PL3984523T3 (pl)	2026-02-02
CA3121920A1 (fr)	2020-06-11
TWI874339B (zh)	2025-03-01
JP2023505232A (ja)	2023-02-08

Publication	Publication Date	Title
MA56226A (fr)	2022-04-20	Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale
EP4081518A4 (fr)	2023-12-27	Associations d'agents de dégradation du récepteur d'?strogènes et d'inhibiteurs de kinase dépendante de cyclines pour le traitement du cancer
MA51200A (fr)	2020-10-07	Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA51739A (fr)	2020-12-16	Compositions pharmaceutiques pour le traitement de la fibrose kystique
MA51796A (fr)	2020-12-16	Procédés et compositions pour l'administration de protéines thérapeutiques
MA52873A (fr)	2021-04-21	Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3790867A4 (fr)	2021-10-13	Inhibiteurs de kdm1a pour le traitement d'une maladie
MA44935A1 (fr)	2019-08-30	Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4 , utilisée pour le traitement d"affections inflammatoires oculaires
EP3468532A4 (fr)	2019-05-22	Dispositif de distribution et composition pharmaceutique pour le traitement de la rhinite
MA50391A (fr)	2021-04-21	Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
EP3883575A4 (fr)	2022-06-15	Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation
EP3668514A4 (fr)	2021-07-14	Formulations pharmaceutiques solides pour le traitement de l'endométriose, de fibromes utérins, du syndrome des ovaires polykystiques et de l'adénomyose
MA52961A (fr)	2021-04-28	Compositions et procédés pour la réduction ou le traitement d'une inflammation
EP3898991A4 (fr)	2022-09-14	Administration périnéale de résinifératoxine pour le traitement de la douleur maladaptative
EP3362096A4 (fr)	2019-06-12	Composition de traitement ophtalmique et véhicule pour l'administration de substances pharmaceutiques ou d'agents thérapeutiques
EP3313379A4 (fr)	2019-04-10	Forme posologique pharmaceutique par voie orale pour l'administration d'un peptide et/ou d'une protéine
EP3876967A4 (fr)	2022-11-23	Microbiote thérapeutique pour le traitement et/ou la prévention d'une dysbiose
EP3856172A4 (fr)	2022-10-05	Compositions pharmaceutiquement actives à base de cannabis et procédés d'utilisation pour traiter des affections gastro-intestinales
EP3790543A4 (fr)	2022-03-30	Compositions et formes posologiques pour administration orale
EP3668517A4 (fr)	2021-02-17	Formulations de microparticules d'antagonistes du récepteur de l'adénosine pour le traitement du cancer
EP3533451A4 (fr)	2020-01-15	Application de paeéniflorin-6'-o-benzène sulfonate en médecine pour le traitement du syndrome de sjögren
MA53099A (fr)	2021-05-12	Formes d'ivosidénib et compositions pharmaceutiques
MA52960A (fr)	2021-04-28	Compositions et procédés pour la réduction ou le traitement de la fibrose
EP3801773A4 (fr)	2022-03-16	Procédés d'utilisation de cd24 pour la prévention et le traitement de la maladie du greffon contre l'hôte et de la mucosite
EP3664850A4 (fr)	2021-05-05	Procédés et compositions pour le traitement d'une maladie intestinale inflammatoire